Plain-English translation of NCT07518043 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a new immunotherapy medicine, works as well and is as safe as , an established cancer immunotherapy, in people who have recently had surgery to remove esophageal cancer, melanoma, or bladder cancer. Both medications help your immune system fight cancer cells that might remain after surgery. The study will track how the medicine moves through your body, how well it works, and what side effects occur.
After surgery to remove certain cancers, there is still a risk that cancer could come back. This medication is designed to prevent that recurrence by boosting your immune system. Researchers want to see if the new treatment is just as effective and safe as the currently approved option.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly over approximately one year to receive injections of the study medication every four weeks. Depending on which group you are randomly assigned to, you will receive either for the full year, or for the first four months followed by for the remaining months. During visits, you will have blood tests, physical exams, and imaging scans to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China